720.4500 8.75 (1.23%)
NSE Aug 05, 2025 15:31 PM
Volume: 3.1M
 

720.45
1.23%
Dolat Capital
In line performance. Arysta's acquisition A strategic fit. UPL's 4QFY19 performance (excluding Arysta Lifescience's two months results) was largely in line with our estimates. The sales/EBITDA/Adj. PAT grew 15.2/0.9/23.5% YoY to ` 65.5/14.3/9.0bn, respectively. The adj.PAT growth of 23.5% YoY was primarily due to a decline in interest costs (down 59.3% YoY) and a lower tax rate (2.6% in 4QFY19 against 23.1% in 4QFY18). Sales rose 15.2% YoY, driven by a volume/value/exchange rate growth of 7.0/5.0/3.0% YoY, respectively. The 4QFY19 and FY19 results include the...
UPL Ltd. is trading above all available SMAs
More from UPL Ltd.
Recommended